Bicocca Open Archive

Logo unimib boa
CIARDULLO, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.043
EU - Europa 2.401
AS - Asia 1.507
SA - Sud America 101
AF - Africa 44
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.114
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.979
SG - Singapore 668
IT - Italia 661
RU - Federazione Russa 500
DE - Germania 370
HK - Hong Kong 294
CN - Cina 276
IE - Irlanda 258
SE - Svezia 253
GB - Regno Unito 101
BR - Brasile 83
ID - Indonesia 63
CA - Canada 57
NL - Olanda 53
IN - India 45
FI - Finlandia 37
VN - Vietnam 34
FR - Francia 30
UA - Ucraina 28
JP - Giappone 23
AT - Austria 21
TR - Turchia 21
AU - Australia 17
BE - Belgio 17
DK - Danimarca 14
KR - Corea 14
EG - Egitto 13
PK - Pakistan 13
IR - Iran 11
RO - Romania 10
PT - Portogallo 9
ZA - Sudafrica 9
DZ - Algeria 8
PL - Polonia 8
BG - Bulgaria 7
ES - Italia 7
AR - Argentina 6
CZ - Repubblica Ceca 6
MA - Marocco 6
CO - Colombia 5
SA - Arabia Saudita 5
TW - Taiwan 5
IQ - Iraq 4
MX - Messico 4
NG - Nigeria 4
TH - Thailandia 4
EC - Ecuador 3
IL - Israele 3
JO - Giordania 3
KG - Kirghizistan 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
CH - Svizzera 2
CY - Cipro 2
MY - Malesia 2
PH - Filippine 2
UZ - Uzbekistan 2
ZM - Zambia 2
ZW - Zimbabwe 2
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
EU - Europa 1
HN - Honduras 1
JE - Jersey 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
TJ - Tagikistan 1
VE - Venezuela 1
Totale 7.114
Salva come PNG Salva come JPEG
Città #
Ann Arbor 702
Singapore 484
Santa Clara 283
Hong Kong 280
Frankfurt am Main 264
Dublin 249
Chandler 201
Milan 187
Fairfield 175
New York 135
Ashburn 103
Wilmington 99
Princeton 96
Chicago 89
Seattle 71
Woodbridge 70
Cambridge 67
Jakarta 61
Houston 60
Altamura 58
London 51
Lawrence 47
Beijing 46
Shanghai 42
San Diego 36
Rome 34
Boardman 28
Helsinki 28
Bari 25
Dong Ket 24
Moscow 23
Los Angeles 22
Monza 22
Nuremberg 21
Nanjing 18
Toronto 18
Brussels 15
Kocaeli 15
Guangzhou 14
Carate Brianza 11
Dearborn 11
Andover 10
Pune 10
Vienna 10
Capurso 9
Groningen 9
Lappeenranta 9
Norwalk 9
Sacramento 9
Sydney 9
Florence 8
Hyderabad 8
Linköping 8
São Paulo 8
Munich 7
Naples 7
Tokyo 7
Amsterdam 6
Changsha 6
Düsseldorf 6
Esslingen am Neckar 6
Hangzhou 6
Wenzhou 6
Bergamo 5
Brno 5
Council Bluffs 5
Falls Church 5
Floridia 5
Laurel 5
Lisbon 5
New Delhi 5
Palermo 5
Paris 5
Riyadh 5
San Mateo 5
Turin 5
Abbadia Lariana 4
Barcelona 4
Cairo 4
Cascina 4
Charlottesville 4
Dallas 4
Jalandhar 4
Kilburn 4
Oujda 4
Pontedera 4
Raleigh 4
Redmond 4
Segrate 4
Southwark 4
Torino 4
Washington 4
Amman 3
Belo Horizonte 3
Berlin 3
Bishkek 3
Cinisello Balsamo 3
Corato 3
Ergolding 3
Fremont 3
Totale 4.611
Salva come PNG Salva come JPEG
Nome #
Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? 356
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction 281
Exploring the landscape of steatotic liver disease in the general US population 235
Endocrinology and Metabolic Diseases (Including Diabetes) 186
Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy 180
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes 172
Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes 171
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes 156
Seasonal variation in estimated cardiovascular risk in patients with type 2 diabetes 133
Lack of awareness of liver organ damage in patients with type 2 diabetes 131
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications 128
Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD 127
Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population 106
Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population 105
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 105
Baseline TSH levels and short-term weight loss after different procedures of bariatric surgery 99
Metabolic and psychological features are associated with weight loss 12 months after sleeve gastrectomy 99
Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines 98
Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017–2018 National Health and Nutrition Examination Survey 97
An unexpected bilateral mass after total thyroidectomy 97
Risk stratification tools for heart failure in the diabetes clinic 96
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016 96
Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study 94
Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories 93
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes 93
Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. women 93
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 90
Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease 89
Impact of the duration of type 2 diabetes on the screening for nonal- coholic fatty liver disease and advanced fibrosis 89
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population 89
Reply to "Liver fibrosis assessed by transient elastography and albuminuria" 85
Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence 84
Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy 84
Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort 83
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 81
Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population 81
Comment on “An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD” 80
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease 79
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting 79
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents 79
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 77
Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general U.S. population 76
Reply [to: Use of FibroScan–AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US...] 76
NAFLD and liver fibrosis are not associated with reduced femoral bone mineral density in the general US population 75
Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study 73
Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients 72
Sex-related association of NAFLD and liver fibrosis with body fat distribution in the general US population 70
Glycated albumin is associated with all-cause and cardiovascular mortality among U.S. adults with and without diabetes: A retrospective cohort study 69
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study 68
Time trends in liver-related mortality in people with and without diabetes: Results from a population based study 68
Global multi-stakeholder endorsement of the MAFLD definition 68
Non-invasive scores of liver fibrosis in morbidly obese patients 67
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population 66
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment 64
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions 64
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes and association with micro- and macrovascular complications 64
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes 63
NAIF: A novel artificial intelligence-based tool for accurate diagnosis of stage F3/F4 liver fibrosis in the general adult population, validated with three external datasets 62
Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes 61
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis 61
Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis 61
Control of Blood Glucose and Cardiovascular Risk Profile 61
Differential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States 58
Twenty-year trends in heart failure among U.S. adults, 1999–2018: The growing impact of obesity and diabetes 58
Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition 57
Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD 56
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States 54
Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis 53
Serum neurofilament light chain levels are associated with all-cause mortality in the general US population 53
Authors' reply to Zou et al 52
Authors' reply to Shang et al. 50
Advances in fibrosis biomarkers in nonalcoholic fatty liver disease 50
Development of a new model of insulin sensitivity in patients with type 2 diabetes and association with mortality 48
Steatotic Liver Disease Phenotypes in the United States: The Impact of Alcohol Consumption Assessment 46
Liver stiffness is associated with all-cause mortality in patients with NAFLD: A systematic review and meta-analysis 45
Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus 45
Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes 43
Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999-2016 42
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes 41
Low 25 (OH) vitamin D levels are associated with increased prevalence of NAFLD and significant liver fibrosis 41
Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence 40
The MAFLD‐MASLD debate: Does cardiovascular risk prediction define the winner? 33
Silent threats: how NAFLD and hypertension team up in young adults, and the role of sex 31
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes 29
Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study 29
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting 28
Prevalence of Noninvasively Detected Clinically Significant Portal Hypertension Among U.S. Adults With and Without Diabetes 26
Authors' response to Guo, Wei et al. 23
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes 23
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 14
Totale 7.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.982
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.982
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202049 0 0 0 0 0 0 0 0 0 0 31 18
2020/2021998 16 30 45 65 72 70 85 116 133 144 88 134
2021/2022741 117 88 99 42 25 52 28 35 50 62 44 99
2022/20231.240 146 226 123 108 92 228 40 71 87 26 58 35
2023/20241.236 89 42 84 102 112 216 166 53 91 53 34 194
2024/20252.987 215 404 309 233 331 220 288 121 343 517 6 0
Totale 7.453